Tuesday, February 21, 2017 4:53:49 PM
Abstract:
"Autologous glioblastoma multiforme tumor cells treated with an antisense oligodeoxynucleotide (AS-ODN) targeting insulin-like growth factor receptor-1 (IGF-1R) are the basis of a vaccine with therapeutic effects on tumor recurrence in a pilot clinical trial. As a preface to continued clinical investigation of this vaccination strategy, we have studied the contribution of an optimized IGF-1R AS-ODN, designated “NOBEL”, to the induction of immunity to mouse GL261 glioma cells. The impact of NOBEL on mechanisms contributing to the development of GL261 immunity was first examined in the periphery. GL261 cells are naturally immunogenic when implanted into the flanks of congenic C57BL/6 mice, immunizing rather than forming tumors in around 50 % of these animals but causing tumors in the majority of mice lacking T and B lymphocytes. Overnight treatment with NOBEL in vitro reduces IGF-1R expression by GL261 cells but has minimal effect on cell viability and does not reduce the capacity of the cells to form tumors upon implantation. In contrast, tumors are extremely rare when GL261 cells are mixed with NOBEL at inoculation into the flanks of C57BL/6, and the recipient mice become immune to subcutaneous and intracranial challenge with untreated GL261. Adaptive immune mechanisms contribute to this effect, as immunocompromised mice fail to either fully control tumor formation or develop immunity following flank administration of the GL261/NOBEL mix. NOBEL’s structure has known immunostimulatory motifs that likely contribute to the immunogenicity of the mix, but its specificity for IGF-1R mRNA is also important as a similarly structured sense molecule is not effective. © 2015, Springer-Verlag Berlin Heidelberg."
I still believe in our drugs and delivery system. The company performance is the issue.
Recent BPTH News
- Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/19/2024 04:14:04 PM
- Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/18/2024 05:57:59 PM
- Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients • GlobeNewswire Inc. • 04/18/2024 11:00:00 AM
- Bio-Path Holdings Expands Global Patent Portfolio • GlobeNewswire Inc. • 04/15/2024 11:00:00 AM
- Bio-Path Holdings Provides 2024 Clinical and Operational Update • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 11:00:34 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 03/08/2024 10:11:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 12:10:34 PM
- Bio-Path Holdings Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/08/2024 12:00:00 PM
- U.S. Index Futures Fluctuate Ahead of Key Jobs Report; Oil Prices Dip • IH Market News • 03/08/2024 11:22:25 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 09:21:27 PM
- Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024 • GlobeNewswire Inc. • 03/01/2024 12:00:00 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 02/29/2024 11:00:30 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 12:01:09 PM
- Bio-Path Holdings Announces 1-for-20 Reverse Stock Split • GlobeNewswire Inc. • 02/21/2024 12:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/02/2024 09:39:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 09:10:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 10:20:23 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/23/2024 09:51:03 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/17/2024 09:52:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:10:09 PM
- Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients • GlobeNewswire Inc. • 01/10/2024 12:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/04/2024 10:18:53 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/22/2023 09:06:16 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/22/2023 09:05:51 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM